UniProt Q13470 · PDB · AlphaFold · Substrate: pEY + Mn · Clone: aa1-510high-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Ponatinib | 99.2% | 0.8% | 78.23 | 0.534 |
| 2 | Ceritinib | 97.3% | 2.7% | 95.44 | 0.618 |
| 3 | Brigatinib | 97.2% | 2.8% | 82.96 | 0.513 |
| 4 | Osimertinib | 92.8% | 7.2% | 97.24 | 0.733 |
| 5 | Pacritinib | 91.8% | 8.2% | 88.64 | 0.452 |
| 6 | Midostaurin | 91.7% | 8.3% | 78.64 | 0.500 |
| 7 | Axitinib | 91.4% | 8.6% | 93.23 | 0.688 |
| 8 | Dabrafenib | 90.2% | 9.8% | 94.74 | 0.633 |
| 9 | Lorlatinib | 87.9% | 12.1% | 97.24 | 0.694 |
| 10 | Gilteritinib | 85.5% | 14.5% | 88.97 | 0.506 |
| 11 | Repotrectinib | 84.1% | 15.9% | 84.21 | 0.608 |
| 12 | Entrectinib | 78.5% | 21.5% | 93.69 | 0.671 |
| 13 | Lazertinib | 68.2% | 31.8% | 97.47 | 0.674 |
| 14 | Fostamatinib | 63.3% | 36.7% | 96.74 | 0.613 |
| 15 | Nintedanib | 56.9% | 43.1% | 90.23 | 0.608 |
| 16 | Cabozantinib | 54.0% | 46.0% | 92.73 | 0.751 |
| 17 | Defactinib | 45.6% | 54.4% | 92.68 | 0.450 |
| 18 | Fedratinib | 43.5% | 56.5% | 96.21 | 0.576 |
| 19 | Alectinib | 35.2% | 64.8% | 95.49 | 0.651 |
| 20 | Crizotinib | 34.2% | 65.8% | 91.39 | 0.581 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 1.01
- Epithelial log2(TPM+1): 2.45
- Fold change: -1.44
- Status: Downregulated
High-confidence drugs
- Ceritinib — inh 97.3% · KISS 43.73
- Osimertinib — inh 92.8% · KISS 43.35
- Lorlatinib — inh 87.9% · KISS 37.37
Selectivity landscape vs inhibition on TNK1
Each point is one of the 92 approved drugs; color = inhibition % on TNK1.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…